Knowledge of critical care nurses' intravenous fluid bolus therapy (FBT) practice remains underexplored. Using a multichoice online survey conducted between September and October 2014, we sought to describe the self-reported practice of critical care nurses located in Australia and New Zealand. Two hundred and ninety-five critical care nurses responded to the survey with most practising in adult ICUs. Overall, 0.9% saline solution was the preferred solution for FBT. However, more Australian than New Zealand respondents preferred 'albumin 4%' (31% versus 3.6%, P <0.01) for FBT. In contrast, more New Zealand respondents preferred 'Plasma-Lyte®'; (33.3% versus 6.4%, P <0.01). Half of the respondents defined FBT as 250 ml administered as quickly as possible. However, FBT volumes ranged from 100 ml to >1000 ml and administration duration from as quickly as possible to 60 minutes. In response to FBT, almost half of the respondents expected an increase in mean arterial pressure of between 11 to 20 mmHg. Similarly, >40% expected a central venous pressure increase >3 mmHg, >70% expected a urinary output increase of 0.5 to 1.0 ml/kg/hr, and >60% expected a decrease in heart rate of >11/min. Overall, 0.9% saline remains the most common solution for FBT, but there are significant national differences in the preference for albumin and Plasma-Lyte. A volume of 250 ml defines a fluid bolus, with a range from 100 ml to >1000 ml, and speed of delivery from stat to 60 minutes. Most nurses expect substantial physiological effects with FBT.
IV fluid therapy plays a fundamental role in the management of critically ill patients. Generally, IV fluids are given to patients to treat or prevent hypovolaemia or are administered as a vehicle for medicines or nutrition [1] [2] [3] . However, in emergency situations and during critical illness, the rapid administration of IV fluid is often deemed necessary 4 . To date, the research agenda has underexplored the role of the nurse in relation to fluid bolus therapy (FBT). Gaps in the literature exist because previous studies have only investigated the types of bolus fluid administered 5, 6 , when bolus fluids are administered 7 , and the triggers associated with FBT 8 . In response, this study sought to provide important information about the reported practices of FBT by critical care nurses, both nationally, and internationally.
Historically, IV fluids have been used in the management of haemodynamically unstable patients since the cholera epidemic of the early 1800s 9 . In contemporary critical care practice, FBT has become a standard of care in the management of hypotensive, septic, oliguric or tachycardic patients 10, 11 . For example, the current Surviving Sepsis Campaign 12 recommends FBT of 20 ml/kg as a key initial therapeutic intervention. However, inappropriate fluid use may be harmful, with emerging evidence linking fluid administration to sodium overload 13 , respiratory compromise 14 and renal impairment 6 . Critical care nurses play a key role in FBT delivery, yet knowledge of nursing FBT practice at a national and international level remains underexplored.
Accordingly, we conducted a survey to describe Australian and New Zealand critical care nurses' self-reported practices of FBT. Specifically, we sought to identify the fluid type, volume and duration of FBT. In addition, we wished to understand clinician involvement in deciding to administer a fluid bolus. Finally, we aimed to identify the most common physiological trigger for, and anticipated physiological response to, FBT.
Materials and methods

Ethical considerations
Human research ethics committee approval was obtained prospectively for Australia (Approval No.: LNR/14/ Austin/305) and New Zealand (Approval No.: 14/STH/127). The survey was anonymous and IP addresses were not stored; there were no privacy issues.
Survey design and pilot testing
We used a structured multi-choice questionnaire to survey critical care nurses. The questionnaire consisted of 19 questions in three parts (Appendix). The first part sought information regarding the type, volume, duration of fluid administration and clinician involvement in FBT. The second part addressed the physiological triggers for, and anticipated physiological response to, FBT. The third part elicited basic demographic and practice-oriented details.
The questionnaire was adapted from a survey originally designed by medical clinical experts for intensive care physicians. To reflect nursing practice, our questionnaire was reviewed by seven experienced intensive care clinicians (two clinically based nursing professors, one associate nurse unit manager, two senior critical care nurses as well as two intensive care medical research fellows who work clinically part-time). Minor changes were made to ensure a nursing focus and to increase the clarity of each question. The questionnaire was then pilot tested amongst 141 intensive care nurses of a tertiary teaching hospital in Victoria, Australia. Due to the small number of changes to the questionnaire, no further pilot testing was performed 15 and the survey was released to this international cohort.
Target population and survey administration
The target population for this survey were critical care nurses working in Australian and New Zealand critical care units. On behalf of the study investigators, all member nurses of the Australian College of Critical Care Nurses (ACCCN) and the Critical Care Nurses Section of the New Zealand Nurses Organisation (NZNO) were invited by their organisations to participate by email if they had previously expressed a willingness to be contacted for research purposes. Responses were obtained over a four-week period from 5 September to 7 October 2014. An electronic reminder was sent after two weeks.
Data management and analysis
Anonymous questionnaire responses were collated using an online survey site (SurveyMonkey®, Palo Alto, CA, USA) to facilitate data management and analysis. All responses are expressed as a percentage of the total number of responses for that question. No imputation has been made as the proportion of missing values was so low: all questions had seven or less missing responses. Data collected by this questionnaire were analysed using simple procedures to calculate proportions. To examine for differences between respondents, multivariable analysis was performed using SPSS statistical package version 19.0 for Windows (SPSS, Chicago, IL, USA) with a P-value of <0.01 for statistical significance. 
Results
Cohort demographics
Overall, 295/1689 (17.5%) critical care nurses responded to the survey invitation; 58% were Australian respondents. Most respondents practised in adult ICUs, were female, held a formal critical care qualification and worked a rotating 'day and night' shift roster (Appendix Table 1 ).
Choice of fluid, volume, and duration of administration
Overall, 0.9% saline solution was the preferred FBT fluid, followed by albumin 4% and Plasma-Lyte® (Baxter International, Deerfield, IL, USA). No respondent selected 6% hydroxyethyl starch for FBT. Half of the respondents defined a fluid bolus as 250 ml, though volumes varied from 100 ml to >1000 ml (Table 1 ). Most respondents stated that a fluid bolus should be delivered 'as quickly as possible', yet identified that speed of delivery extended from 'less than 15 minutes' to '30 to 60 minutes' ( Table 1) .
Clinician involvement in deciding to administer FBT
The 'Critical Care/ICU Registrar' was identified as the primary clinician responsible for deciding to give a fluid bolus ( Figure 1 ). However, the majority of respondents stated they 'initiated' the discussion with the intensive care doctor most of the time (Figure 2 ). When asked if they independently gave a fluid bolus with a written 'existing' order, most respondents stated between '50% and 100% of the time' or '100% of the time' (Table 1) . When asked how often they independently gave a fluid bolus without a written 'existing' order, most respondents indicated 'Never' or 'less than 50% of the time' (Table 1 ).
Physiological triggers for FBT and the anticipated physiological response
Of five common physiological abnormalities listed, hypotension was identified as the most common FBT trigger (70.5%), followed by oliguria (11.1%). Fewer respondents identified tachycardia, low central venous pressure or low mean pulmonary artery pressure as common triggers. However, 22 respondents (7.5%) commented that multiple physiological abnormalities used in combination typically trigger FBT.
In the hour following a fluid bolus, almost half of the respondents expected an increase in mean arterial pressure of between 11 and 20 mmHg ( Figure 3 ). Similarly, >40% expected a central venous pressure increase >3 mmHg (Figure 4 ), >70% expected a urine output increase of 0.5 to 1.0 ml/kg/hr ( Figure 5) , and >60% expected a decrease in heart rate of >11 ( Figure 6 ). However, for these physiological parameters, between 5% and 17% of respondents were 'unsure' about their anticipated physiological response. 
Response differences depending on country of practice
The differences between the two countries are shown in Table 2 . The most important difference between the two countries related to choice of fluid, with more Australian than New Zealand respondents preferring albumin 4% (31% versus 3.6%, P<0.01) for FBT. In contrast, more New Zealand respondents preferred Plasma-Lyte (33.3% versus 6.4%, P<0.01).
Discussion
Summary of major findings
In this bi-national survey, the majority of our critical care nurse respondents considered a typical fluid bolus to be 0.9% saline and a volume of 250 ml. However, the volume of a fluid considered to constitute FBT varied from 100 ml to >1000 ml. Furthermore, while the most popular speed of delivery was 'as quickly as possible', many respondents accepted durations of up to 60 minutes. Strikingly, respondents were either unsure about the anticipated physiological effect or anticipated strong physiological responses to FBT. Finally, there are national differences in the preference for albumin or Plasma-Lyte as the fluid of choice for FBT.
Comparison with previous studies
The physiological rationale for giving FBT is to restore or optimise cardiac preload to correct haemodynamic instability, restore tissue perfusion and maintain organ function 4 . The most effective approach to FBT in critically ill patients remains controversial, despite recent conceptual models 4 and consensus guidelines 16 . Clinical decisions regarding which fluid to use, how much fluid should be used and when to use fluid have been informed more by opinion than evidence 17 . Little is known about the actual physiological response to fluid administration 4, 7, 13, 18 . In our study the nurses identified the ICU registrar as the primary individual responsible for deciding that a patient needs a fluid bolus, while most indicated that they initiated the conversation. Consequently, the nurses' reported type and volume of FBT may be in part reflective of contemporary medical practice. Thereby, exploring critical care nurse knowledge and practice is important as this is a nursedelivered intervention, and may be nurse-initiated.
Overall, 0.9% saline was the preferred FBT type identified by our Australian and New Zealand respondents and has been extensively studied in randomised controlled trials of critically ill patients 5, 6 . In 2010, Finfer and colleagues 8 performed a crosssectional study involving 391 ICUs drawn from 25 countries. Overall, 4488 episodes of FBT involving 1955 patients during the 24-hour study period were examined. Triggers for FBT were perceived signs of impaired perfusion (1526/3419, 44.6%) and the desire to correct abnormal vital signs (1189/3419, 24.8%). Colloids were given more frequently than crystalloids; however, after adjustment for patient and prescriber characteristics, the choice of fluid varied markedly between countries.
Knowledge of the physiological effects of FBT may inform our clinical decisions, however the short-term physiological effect of FBT remains vastly underexplored 7 . Some insight can be gained from a recent single-centre prospective observational study that was conducted to evaluate the efficacy of FBT in 50 ICU patients with severe sepsis and septic shock 19 . In this population, hypotension (76%) and increased vasopressor requirements (60%) were the most common indications for FBT. The median fluid bolus volume administered over the first 24 hours was 750 ml (IQR 500 to 1750 ml). One hour after FBT administration, with a concomitant increase in vasoactive therapy, mean arterial pressure had increased by 2 mmHg, central venous pressure had risen by 2 mmHg, while heart rate and urine output were unaffected. Such findings demonstrate that the documented physiological effects of FBT are markedly different from the expectations of our cohort of nurses. In Australia, albumin is made available from the Red Cross and supplied to hospitals for free. It is a colloid, and as such, smaller volumes of fluid may be required to achieve desired haemodynamic effects 5 . However, albumin is effectively suspended in 0.9% saline, which delivers a supra-physiological chloride load. Avoidance of chloride-rich solutions has been associated with a significant decrease in the incidence of acute kidney injury and renal replacement therapy use 20 . In New Zealand, albumin solutions are costly, and the preferred fluid for FBT is Plasma-Lyte. It is a balanced crystalloid solution with a lower, more physiological, chloride concentration. However, the relationship between Plasma-Lyte, albumin and patientcentred outcomes has yet to be resolved via an adequately powered multicentre randomised controlled trial 21 . Moreover, the fluid preferences by our survey respondents may reflect local ecological conditions associated with the availability of fluids and trends in fluid prescription practices 20 .
Implications
Critical care nurses are at the forefront of IV FBT administration, monitoring, and management for critically ill patients. Findings of this study demonstrate national differences in preference for fluid type and that the anticipated physiological effects of FBT are dissociated from current evidence. In addition, while the aim of this study was not to investigate how critical care nurses make FBT decisions, the degree of variability in the responses suggests that practice is inconsistent between institutions, regions and countries. Given the potential clinical implications for critically ill patients, there remains an urgent need to rigorously and critically evaluate FBT and its implications for patient safety, educational training and quality improvement activities.
Strengths and limitations
Our study has several strengths. First, it was based on an established questionnaire, which had been piloted by critical care nurses. Second, the responses were drawn from an international cohort of nurses. Third, to our knowledge, this is the largest survey of self-reported FBT practice by critical care nurses. Conversely, the study has some limitations. Broadly, the questionnaire was tailored toward nurses caring for adult critically ill patients and as such may not appropriately reflect the FBT practice in paediatric, emergency department or post-anaesthesia care settings. In addition, questions about anticipated physiological responses to FBT may not have provided enough clinical information on which to make a definitive clinical judgement. Nonetheless, although our findings reflect what nurses say they do rather than what they actually do, they provide the first dataset on self-reported preferences and a baseline for future comparisons.
Conclusion
In our study of a bi-national cohort of critical care nurses, 0.9% saline is the preferred bolus fluid, a volume of 250 ml defined a fluid bolus (though volumes ranged from 100 ml to >1000 ml) and speed of delivery was identified from stat to 60 minutes. There were national differences in the preference for albumin and Plasma-Lyte. Most nurses expect FBT to have substantial physiological effects, a belief dissociated from current evidence. Our study contributes to the foundational understanding of this complex area of nursing practice, and justifies more extensive investigations. 
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